DRKS00016746已完成不适用

Helminth infection during pregnancy alters immune responses at the fetomaternal interface - HelmVit_Pilotstudy

Institut für Mikrobiologie, Immunologie und Hygiene, Technische Universität München0 个研究点目标入组 102 人开始时间: 2019年4月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Presence of written consent
•- Age > 18 years
•- feminine
•- Persons who are legally competent and mentally able to understand and follow the instructions of the study staff.
•- Patient information and written declaration of consent of the test person
•- Adequate bone marrow reserve with a peripheral granulocyte count >1500/µl and platelet count >40.000/µl
•- No condition after recurrent thrombosis or pulmonary embolism
•- no serious abnormalities during the physical examination
•- Documentation of known anaphylaxias

•- Presence of the following autoimmune diseases: Anti-phospholipid, antibody syndrome, Goodpasture syndrome, Sjögren syndrome, rheumatoid arthritis, lupus erythematosus, sarcoidosis, anti-neutrophilic cytoplasmic antibodies (ANCA syndrome), scleroderma, chronic polychondritis
•- The following known immunodepressing diseases: X-chromosomal A-?-Globulinemia, severe combined immunodeficiency (SCID), common variable immunedeficiency (CVID), selective IgA deficiency
•- known hepatitis B and/or C, HIV, HSV, CMV, syphilis, toxoplasmosis infection
•- other, severe, active infection
•- ongoing corticosteroid treatment
•- transfusion-dependent anemia
•- any other disease or medical treatment which, in the opinion of the investigator, would militate against participation in the study, e.g. (pre-)eclampsia, HELLP syndrome
•- Persons who have a dependent/labour relationship with the sponsor or investigator.
•- known cancers currently or in the past

发起方

Institut für Mikrobiologie, Immunologie und Hygiene, Technische Universität München